These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38922779)
1. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. Nitsche C; Ioannou A; Patel RK; Razvi Y; Porcari A; Rauf MU; Bandera F; Aimo A; Emdin M; Martinez-Naharro A; Venneri L; Petrie A; Wechalekar A; Lachmann H; Hawkins PN; Gillmore JD; Fontana M Eur J Heart Fail; 2024 Sep; 26(9):2008-2012. PubMed ID: 38922779 [TBL] [Abstract][Full Text] [Related]
2. Biomarkers and Prediction of Prognosis in Transthyretin-Related Cardiac Amyloidosis: Direct Comparison of Two Staging Systems. Cappelli F; Martone R; Gabriele M; Taborchi G; Morini S; Vignini E; Allinovi M; Di Gioia M; Bartolini S; Di Mario C; Perfetto F Can J Cardiol; 2020 Mar; 36(3):424-431. PubMed ID: 32145869 [TBL] [Abstract][Full Text] [Related]
3. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy. Sanne Bøjet L; Bertil L; Anders Lehmann Dahl P; Jens Kæstel S; Tor Skibsted C; Steen Hvitfeldt P Ann Med; 2024 Dec; 56(1):2398735. PubMed ID: 39247984 [TBL] [Abstract][Full Text] [Related]
4. A new staging system for cardiac transthyretin amyloidosis. Gillmore JD; Damy T; Fontana M; Hutchinson M; Lachmann HJ; Martinez-Naharro A; Quarta CC; Rezk T; Whelan CJ; Gonzalez-Lopez E; Lane T; Gilbertson JA; Rowczenio D; Petrie A; Hawkins PN Eur Heart J; 2018 Aug; 39(30):2799-2806. PubMed ID: 29048471 [TBL] [Abstract][Full Text] [Related]
5. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Law S; Bezard M; Petrie A; Chacko L; Cohen OC; Ravichandran S; Ogunbiyi O; Kharoubi M; Ganeshananthan S; Ganeshananthan S; Gilbertson JA; Rowczenio D; Wechalekar A; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Damy T; Fontana M; Gillmore JD Eur Heart J; 2022 Jul; 43(27):2622-2632. PubMed ID: 35608040 [TBL] [Abstract][Full Text] [Related]
6. Prognosis of Light Chain Amyloidosis With Preserved LVEF: Added Value of 2D Speckle-Tracking Echocardiography to the Current Prognostic Staging System. Barros-Gomes S; Williams B; Nhola LF; Grogan M; Maalouf JF; Dispenzieri A; Pellikka PA; Villarraga HR JACC Cardiovasc Imaging; 2017 Apr; 10(4):398-407. PubMed ID: 27639764 [TBL] [Abstract][Full Text] [Related]
7. Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy. Law S; Petrie A; Chacko L; Cohen OC; Ravichandran S; Gilbertson JA; Rowczenio D; Wechalekar AD; Martinez-Naharro A; Lachmann HJ; Whelan CJ; Hutt DF; Hawkins PN; Fontana M; Gillmore JD Heart; 2022 Mar; 108(6):474-478. PubMed ID: 33990410 [TBL] [Abstract][Full Text] [Related]
8. Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. Grogan M; Scott CG; Kyle RA; Zeldenrust SR; Gertz MA; Lin G; Klarich KW; Miller WL; Maleszewski JJ; Dispenzieri A J Am Coll Cardiol; 2016 Sep; 68(10):1014-20. PubMed ID: 27585505 [TBL] [Abstract][Full Text] [Related]
9. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Siepen FAD; Bauer R; Voss A; Hein S; Aurich M; Riffel J; Mereles D; Röcken C; Buss SJ; Katus HA; Kristen AV Clin Res Cardiol; 2018 Feb; 107(2):158-169. PubMed ID: 28956153 [TBL] [Abstract][Full Text] [Related]
10. Prognostic mortality factors in advanced light chain cardiac amyloidosis: A prospective cohort study. Zaroui A; Kharoubi M; Gounot R; Oghina S; Degoutte C; Bezard M; Galat A; Guendouz S; Roulin L; Audard V; Leroy V; Teiger E; Poullot E; Molinier-Frenkel V; Le Bras F; Belhadj K; Bastard JP; Fellahi S; Shourick J; Lemonier F; Damy T ESC Heart Fail; 2024 Jun; 11(3):1707-1719. PubMed ID: 38444090 [TBL] [Abstract][Full Text] [Related]
11. Low QRS Voltages in Cardiac Amyloidosis: Clinical Correlates and Prognostic Value. Cipriani A; De Michieli L; Porcari A; Licchelli L; Sinigiani G; Tini G; Zampieri M; Sessarego E; Argirò A; Fumagalli C; De Gaspari M; Licordari R; Russo D; Di Bella G; Perfetto F; Autore C; Musumeci B; Canepa M; Merlo M; Sinagra G; Gregori D; Iliceto S; Perazzolo Marra M; Cappelli F; Rapezzi C JACC CardioOncol; 2022 Nov; 4(4):458-470. PubMed ID: 36444225 [TBL] [Abstract][Full Text] [Related]
12. Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study. Aimo A; Vergaro G; Castiglione V; Fabiani I; Barison A; Gentile F; Ferrari Chen YF; Giorgetti A; Genovesi D; Buda G; Franzini M; Piepoli M; Moscardini S; Rapezzi C; Fontana M; Passino C; Emdin M Eur J Prev Cardiol; 2024 Aug; 31(11):1410-1417. PubMed ID: 38456769 [TBL] [Abstract][Full Text] [Related]
13. Role of natriuretic peptide to predict cardiac abnormalities in patients with hereditary transthyretin amyloidosis. Damy T; Deux JF; Moutereau S; Guendouz S; Mohty D; Rappeneau S; Guellich A; Hittinger L; Loric S; Lefaucheur JP; Plante-Bordeneuve V Amyloid; 2013 Dec; 20(4):212-20. PubMed ID: 23964755 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of a 6-Minute Walk Test in Patients With Transthyretin Cardiac Amyloidosis. Ioannou A; Fumagalli C; Razvi Y; Porcari A; Rauf MU; Martinez-Naharro A; Venneri L; Moody W; Steeds RP; Petrie A; Whelan C; Wechalekar A; Lachmann H; Hawkins PN; Solomon SD; Gillmore JD; Fontana M J Am Coll Cardiol; 2024 Jul; 84(1):43-58. PubMed ID: 38739065 [TBL] [Abstract][Full Text] [Related]
15. Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide. Klaassen SHC; Tromp J; Nienhuis HLA; van der Meer P; van den Berg MP; Blokzijl H; van Veldhuisen DJ; Hazenberg BPC Am J Cardiol; 2018 Jan; 121(1):107-112. PubMed ID: 29153245 [TBL] [Abstract][Full Text] [Related]
16. Noninvasive risk stratification of patients with transthyretin amyloidosis. Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252 [TBL] [Abstract][Full Text] [Related]
17. Response to therapy with tafamidis 61 mg in patients with cardiac transthyretin amyloidosis: real-world experience since approval. Aus dem Siepen F; Meissner C; Hofmann E; Hein S; Nagel C; Hegenbart U; Schönland SO; Andre F; Frey N; Kristen AV Amyloid; 2024 Sep; 31(3):226-231. PubMed ID: 39018203 [TBL] [Abstract][Full Text] [Related]
18. Stratifying Disease Progression in Patients With Cardiac ATTR Amyloidosis. Ioannou A; Cappelli F; Emdin M; Nitsche C; Longhi S; Masri A; Cipriani A; Zampieri M; Colio F; Poledniczek M; Porcari A; Razvi Y; Aimo A; Vergaro G; De Michieli L; Rauf MU; Patel RK; Villanueva E; Lustig Y; Venneri L; Martinez-Naharro A; Lachmann H; Wechalekar A; Whelan C; Petrie A; Hawkins PN; Solomon S; Gillmore JD; Fontana M J Am Coll Cardiol; 2024 Mar; 83(14):1276-91. PubMed ID: 38530684 [TBL] [Abstract][Full Text] [Related]
19. Value of troponin and NT-proBNP to screen for cardiac amyloidosis after carpal tunnel syndrome surgery. Noory N; Westin O; Fosbøl E; Maurer MS; Gustafsson F Int J Cardiol; 2024 Nov; 415():132469. PubMed ID: 39181411 [TBL] [Abstract][Full Text] [Related]
20. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis. Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]